By integrating information from a well-understood drug agent, a large dataset in patients with the active molecule tramiprosate, novel genetic markers and insights into the pathology of Alzheimer’s disease (AD), we have created ALZ-801, an optimized prodrug of tramiprosate. ALZ-801 is one of the few drug candidates in advanced stages of clinical testing in AD, a pill with a favorable safety profile and the potential to modify an underlying cause of the disease.
2016-03-30T19:20:43+00:00 March 11th, 2016|
Results Support Advancement of ALZ‐801 into Pivotal Clinical Studies in APOE4/4 Homozygous Subjects with Mild to Moderate Alzheimer’s Disease Data Presented at the 14th Annual International Athens/Springfield Symposium on Advances in Alzheimer Therapies Conference [...]
2016-03-28T15:05:24+00:00 March 11th, 2016|
FRAMINGHAM, Mass., March 11, 2016 – Alzheon, Inc., a clinical‐stage biopharmaceutical company focused on brain health, memory and aging, announced today that Dennis H. Langer, MD, JD, has been appointed to its Board of [...]
2016-04-04T01:56:48+00:00 January 26th, 2016|
Alzheon is focused on developing treatments for patients with Alzheimer’s disease and other neurological and psychiatric disorders. The company’s lead clinical product candidate, ALZ-801, is an oral inhibitor of amyloid aggregation and neurotoxicity—hallmarks of [...]